 |
BioWorld-Insight-2011-06-06
Biotech IPOs Up 33%: Why and What to Expect Next
InterMune's CRL Response Highlights Pros, Cons of IPF
At its recent analyst day, InterMune Inc. updated investors on plans for the confirmatory trial required to obtain U.S. approval for its idiopathic pulmonary fibrosis (IPF) drug Esbriet (pirfenidone), which the FDA slapped with a complete response letter last year.